Desipramine potentiation of the acute depressant effects of ethanol: Modulation by α2-adrenoreceptors and stress

被引:19
作者
Boyce-Rustay, Janel M. [1 ]
Palachick, Benjamin [1 ]
Hefner, Kathryn [1 ]
Chen, Yi-Chyan [2 ]
Karlsson, Rose-Marie [3 ,4 ]
Millstein, Rachel A. [1 ]
Harvey-White, Judith [5 ]
Holmes, Andrew [1 ]
机构
[1] NIAAA, Sect Behav Sci & Genet, Lab Integrat Neurosci, NIH, Rockville, MD 20852 USA
[2] TriServ Gen Hosp, Natl Def Med Ctr, Dept Psychiat, Taipei, Taiwan
[3] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD USA
[4] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[5] NIAAA, Lab Physiol Studies, NIH, Rockville, MD 20852 USA
关键词
Ethanol; Norepinephrine; Norepinephrine transporter; Sedation; Stress; Serotonin;
D O I
10.1016/j.neuropharm.2008.06.032
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Ethanol exerts effects on the brain noradrenergic system, and these are thought to contribute to the sedative/hypnotic (depressant) effects of ethanol. Recent studies suggest that the norepinephrine transporter (NET) plays an important role in modulating ethanol's depressant effects. The aim of the present study was to further characterize this role. Transporter blockers with varying affinity for NET versus the serotonin transporter (desipramine > fluoxetine > citalopram) were tested for their ability to alter ethanol's depressant effects, and for comparison, hypothermic effects. Effects of desipramine on another depressant, pentobarbital, were examined. Desipramine potentiation of ethanol's depressant effects was assessed following depletion of brain norepinephrine via N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSPA) treatment, or depletion of brain 5-HT via para-chlorophenylalanine methyl ester hydrochloride (PCPA) treatment. The effects of co-administration of either the selective alpha 2-adrenoreceptor agonist (dexmedetomidine) or the selective alpha 2-adrenoreceptor antagonist (atipamezole) on desipramine's effect on ethanol's depressant effects were examined. Given the close link between stress, ethanol and norepinephrine, desipramine potentiation of ethanol's depressant effects was tested following repeated forced swim stress. Results showed that desipramine, but not SERT-selective doses of citalopram or fluoxetine, strongly potentiated the depressant (not hypothermic) effects of ethanol. These effects were mimicked by dexmedetomidine and blocked by atipamezole, but not by depletion of either norepinephrine or 5-HT. Desipramine potentiation of ethanol's depressant effects was abolished following repeated stress. Present findings further support a major role for NET and the alpha 2-adrenoreceptor in modulating the depressant effects of ethanol, with possible implications for understanding the role of noradrenergic dysfunction in stress-related alcoholism. Published by Elsevier Ltd.
引用
收藏
页码:803 / 811
页数:9
相关论文
共 100 条
[1]   ALPHA2-ADRENERGIC AGENTS IN ANESTHESIA [J].
AANTAA, R ;
SCHEININ, M .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1993, 37 (05) :433-448
[2]   An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance [J].
Aston-Jones, G ;
Cohen, JD .
ANNUAL REVIEW OF NEUROSCIENCE, 2005, 28 :403-450
[3]   LOW-DOSES OF ETHANOL DISRUPT SENSORY RESPONSES OF BRAIN NORADRENERGIC NEURONS [J].
ASTONJONES, G ;
FOOTE, SL ;
BLOOM, FE .
NATURE, 1982, 296 (5860) :857-860
[4]  
ASTONJONES G, 1981, J NEUROSCI, V1, P876
[5]  
BEALER SL, 1993, J PHARMACOL EXP THER, V264, P734
[6]  
Bennett B, 1998, MAMM GENOME, V9, P969
[7]   Deletion of the α1 or β2 subunit of GABAA receptors reduces actions of alcohol and other drugs [J].
Blednov, YA ;
Jung, S ;
Alva, H ;
Wallace, D ;
Rosahl, T ;
Whiting, PJ ;
Harris, RA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (01) :30-36
[8]  
BLUM K, 1972, CURR THER RES CLIN E, V14, P324
[9]  
Boehm SL, 2006, ADV PHARMACOL, V54, P171, DOI 10.1016/S1054-3589(06)54008-6
[10]   Role of H3-receptor-mediated signaling in anxiety and cognition in wild-type and Apoe-/- mice [J].
Bongers, G ;
Leurs, R ;
Robertson, J ;
Raber, J .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (03) :441-449